This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

  1. Home
  2. Professionals
  3. Gustavo Akkerman
  1. Back
Gustavo Akkerman
Gustavo Akkerman
Associate
New York +1 212 841 1005 gakkerman@cov.com Download V-card
View Less

Gustavo Akkerman represents U.S. and international clients in a broad range of domestic and cross-border corporate transactions, including in the life sciences and financial services industries. He also advises clients on international anti-corruption matters. A licensed attorney in Brazil and a native Portuguese speaker, Mr. Akkerman helps clients navigate the Latin American business and legal environments.

Prior to joining Covington & Burling, Mr. Akkerman practiced law as an associate in the Corporate and M&A practices of a leading Brazilian law firm.

  • TRC Companies (NYSE: TRR), an engineering, environmental consulting and construction management firm, in its $595 million acquisition by New Mountain Capital.
  • Astellas Pharma in its $384 million acquisition of Ocata Therapeutics (Nasdaq: OCAT), a biotechnology company specializing in the development of stem cell-based treatments in regenerative medicine.
  • ITOCHU Corporation and ITOCHU International in the sale of PrimeSource Building Products, a North American distributor of building materials, to Platinum Equity. 
  • Allergan, in the $500 million sale of its Anda distribution business to Teva Pharmaceutical Industries.
  • Advising Merck on the multi-year post-merger integration of Schering-Plough Corporation in certain Latin American countries, and on the post-merger integration of Cubist Pharmaceuticals and Idenix Pharmaceuticals.
  • OrbiMed Advisors in secured debt and equity investments in biotechnology, pharmaceutical and medical device companies.
  • Several U.S. based and foreign private equity funds managed by a significant private equity management group and with assets of more than $1.3 billion in aggregate, in connection with subscription credit facilities secured by their uncalled capital commitments. 
  • Tricadia Capital Management as an anchor equity investor in the recapitalization of Bridgeview Bancorp, Inc., a regional bank holding company based in the Chicago metropolitan area.
  • Advised Acorda Therapeutics, Inc., in its public offering of $345 million of 1.75% Convertible Senior Notes due 2021 and in a $75 million private placement of shares of common stock.
  • Represented the underwriters in the U.S. initial public offering of ordinary shares of uniQure N.V., an Amsterdam-based gene therapy company.
  • Represented the underwriters in the initial public offering of Retrophin, Inc., a biopharmaceutical company focused on treatment of catastrophic diseases.
  • Represented the underwriters in the initial public offering of Bankwell Financial Group, Inc., the bank holding company for Bankwell, a community bank based in New Canaan, Connecticut.
  • Represented a Fortune 50 company and a Fortune Global 500 company in whistleblower Foreign Corrupt Practices Act investigations.
  • Advised a Fortune 100 company and a Fortune Global 500 company in anti-corruption compliance risk assessments.
View More View Less

Practices

Education

Stanford Law School, LL.M., 2013

Escola de Direito de São Paulo da Fundação Getúlio Vargas, LL.B., 2009

  • Valedictorian

Bar Admissions

  • Brazil
  • New York

Languages

  • Portuguese
  • Spanish